Gene therapy for unresectable hepatocellular carcinoma using recombinant human adenovirus type 5

Dong, Jun; Li, Wang; Dong, Annan; Mao, Siyue; Shen, Lujun; Sheng, Li; Gong, Xiao; Wu, Peihong

doi:10.1007/s12032-014-0095-4

Cited by 17 publications

(19 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recombinant unarmed adenoviruses demonstrate low toxicity (Grade 1–2) and impressive oncolytic potential which can be boosted by additional expression of immunostimulatory molecules (IFN-gamma, GM-CSF) or p53 (rAd-p53) [ 42 , 43 , 44 ]. More than 400 patients have been treated with rAd-p53, mainly in combination with chemotherapy [ 45 ], radiotherapy [ 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 ] and tumor resection [ 54 ] with various efficacy. Thus the overall response rate for combined treatment with cisplatin of malignant pleural effusion caused by lung cancer has reached an encouraging 82% [ 50 ].…”

Section: Oncolytic Viruses In Clinical Trialsmentioning

confidence: 99%

Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes

Malogolovkin

Gasanov

Egorov

et al. 2021

Viruses

View full text Add to dashboard Cite

Recent cancer immunotherapy breakthroughs have fundamentally changed oncology and revived the fading hope for a cancer cure. The immune checkpoint inhibitors (ICI) became an indispensable tool for the treatment of many malignant tumors. Alongside ICI, the application of oncolytic viruses in clinical trials is demonstrating encouraging outcomes. Dozens of combinations of oncolytic viruses with conventional radiotherapy and chemotherapy are widely used or studied, but it seems quite complicated to highlight the most effective combinations. Our review summarizes the results of clinical trials evaluating oncolytic viruses with or without genetic alterations in combination with immune checkpoint blockade, cytokines, antigens and other oncolytic viruses as well. This review is focused on the efficacy and safety of virotherapy and the most promising combinations based on the published clinical data, rather than presenting all oncolytic virus variations, which are discussed in comprehensive literature reviews. We briefly revise the research landscape of oncolytic viruses and discuss future perspectives in virus immunotherapy, in order to provide an insight for novel strategies of cancer treatment.

show abstract

Section: Oncolytic Viruses In Clinical Trialsmentioning

confidence: 99%

Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes

Malogolovkin

Gasanov

Egorov

et al. 2021

Viruses

View full text Add to dashboard Cite

show abstract

“…A total of 3,996 patients were included in the 22 articles (7,, including 7 articles (7,(12)(13)(14)(15)(16)(17) on hepatocellular carcinoma (HCC), 5 articles (18)(19)(20)(21)(22) on lung cancer, 5 articles on melanoma (23)(24)(25)(26)(27), 2 studies (28,29) on pancreatic cancer, 1 article ( 30) on head and neck cancer, and 1 study ( 31) on esophageal cancer, and 1 study ( 32) was on cancer. Five types of OVs (H101, HF10, Pexa-Vec, Reolysin and T-VEC) were used among the included studies.…”

Section: Characteristics Of the Included Studies And Quality Assessmentmentioning

confidence: 99%

The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: a systematic review and meta-analysis

Gao¹,

Ding²,

Wang³

2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: Cancer treatment remains one of the most formidable challenges worldwide. Some novel treatment strategies, including molecularly targeted therapy, gene therapy, and cellular immunotherapy, have also been investigated to improve therapeutic effects for cancer patients and have demonstrated unexpected positive effects. This systematic review and meta-analysis evaluated the efficacy and safety of oncolytic virus (OV) monotherapy or combination therapy for intermediate to advanced solid tumors. Methods: We retrieved articles from PubMed, Embase, Web of Science, CNKI, Wanfang and VIP. The quality of the included studies was assessed by Review Manager Software version 5.3. STATA software was used to perform meta-analyses of efficacy, overall survival (OS) and adverse reactions.Results: A total of 22 studies involving 3,996 patients were included in this analysis, including 13 H101 studies, 5 T-VEC studies, 2 Pexa-Vec studies, 1 HF10 study and 1 Reolysin study. Regarding oncolytic adenovirus H101, meta-analysis showed that patients treated with H101 monotherapy or H101 combined with chemotherapy had a significantly higher objective response rate (ORR) than those treated with chemotherapy. Patients in the H101 and T-VEC groups had significantly longer effect size (ES) than the control group patients. The odds ratio (OR) and ES of patients with hepatocellular carcinoma, lung cancer and melanoma treated with OV were analyzed. For the safety profile, the total incidence of adverse reactions was similar in both groups. In terms of the other OVs, according to a systematic review, we found that after Reolysin treatment, the ORR was 26.9% in patients with head and neck cancer. The phase I study of HF10 exhibited some therapeutic potential. The adverse events (AEs) associated with the other OVs mainly included fever, nausea and vomiting, leukopenia, and hypotension. Discussion: OVs are effective and well tolerated for the treatment of intermediate to advanced solid cancer and represent a promising therapeutic approach for solid cancers.

show abstract

“…In the case of a tumor cell, p53 is usually mutated. Hence, the viral genome replicates, which results in eventual cell death [47].…”

Section: Types Of Gene Therapymentioning

confidence: 99%

Current Status of Gene Therapy in Hepatocellular Carcinoma

Reghupaty

Sarkar

2019

Cancers

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer related deaths world-wide. Liver transplantation, surgical resection, trans-arterial chemoembolization, and radio frequency ablation are effective strategies to treat early stage HCC. Unfortunately, HCC is usually diagnosed at an advanced stage and there are not many treatment options for late stage HCC. First-line therapy for late stage HCC includes sorafenib and lenvatinib. However, these treatments provide only an approximate three month increase in survival. Besides, they cannot specifically target cancer cells that lead to a wide array of side effects. Patients on these drugs develop resistance within a few months and have to rely on second-line therapy that includes regorafenib, pembrolizumab, nivolumab, and cabometyx. These disadvantages make gene therapy approach to treat HCC an attractive option. The two important questions that researchers have been trying to answer in the last 2–3 decades are what genes should be targeted and what delivery systems should be used. The objective of this review is to analyze the changing landscape of HCC gene therapy, with a focus on these two questions.

show abstract

Gene therapy for unresectable hepatocellular carcinoma using recombinant human adenovirus type 5

Cited by 17 publications

References 17 publications

Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes

Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes

The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: a systematic review and meta-analysis

Current Status of Gene Therapy in Hepatocellular Carcinoma

Contact Info

Product

Resources

About